The role of HER2 in cancer therapy and targeted drug delivery.

[1]  B. Qin,et al.  Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. , 2010, Molecular pharmaceutics.

[2]  D. Dizon,et al.  HER-dimerization inhibitors: evaluating pertuzumab in women's cancers , 2010, Expert opinion on biological therapy.

[3]  Werner Scheuer,et al.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. , 2009, Cancer research.

[4]  E. Winer,et al.  Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Mahato,et al.  Pharmaceutical perspectives of cancer therapeutics , 2009 .

[6]  C. Parise,et al.  Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999–2004 , 2009, The breast journal.

[7]  D. Roukos.  Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance , 2009, Annals of Surgical Oncology.

[8]  R. Brierley.  2009 ASCO Annual Meeting , 2009 .

[9]  E. Van Cutsem,et al.  Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Mahato,et al.  siRNA delivery and targeting. , 2009, Molecular pharmaceutics.

[11]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[12]  R. Radhakrishnan,et al.  Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study. , 2009, Biophysical journal.

[13]  S. Morrison,et al.  Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer , 2009, Molecular Cancer Therapeutics.

[14]  Pamela Basto,et al.  HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy , 2008, ChemMedChem.

[15]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[16]  R. Neve,et al.  Unraveling the biologic and clinical complexities of HER2. , 2008, Clinical breast cancer.

[17]  S. Stein,et al.  Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer , 2008, Nature Clinical Practice Oncology.

[18]  G. Berx,et al.  The cell-cell adhesion molecule E-cadherin , 2008, Cellular and Molecular Life Sciences.

[19]  V. Chernomordik,et al.  Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging , 2008, Clinical Cancer Research.

[20]  M. Birkner,et al.  A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC) , 2008 .

[21]  S. Tanuma,et al.  Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods , 2008, Breast cancer.

[22]  M. Cher,et al.  CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone , 2008, Molecular Cancer Research.

[23]  J. Fricker.  2008 Gastrointestinal Cancers Symposium , 2008 .

[24]  V. Krasnykh,et al.  Modification of Adenovirus Capsid with a Designed Protein Ligand Yields a Gene Vector Targeted to a Major Molecular Marker of Cancer , 2007, Journal of Virology.

[25]  G Brockhoff,et al.  Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation , 2007, Cell proliferation.

[26]  F. Lordick,et al.  HER2 positivity in advanced gastric cancer is comparable to breast cancer , 2007 .

[27]  R. Nahta,et al.  Trastuzumab: triumphs and tribulations , 2007, Oncogene.

[28]  M. Hung,et al.  Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family* , 2007, Journal of Biological Chemistry.

[29]  Marc Birringer,et al.  A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. , 2007, Cancer research.

[30]  Vladimir Tolmachev,et al.  Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.

[31]  N. Spector,et al.  HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors , 2007, Breast Cancer Research.

[32]  R. Pehrson,et al.  Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. , 2007, Cancer research.

[33]  T. Daniels,et al.  Long-term immunity elicited by antibody–cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies , 2007, Cancer Immunology, Immunotherapy.

[34]  J. D. de Bono,et al.  Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). , 2007, European journal of cancer.

[35]  R. Zeillinger,et al.  In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway , 2007, British Journal of Cancer.

[36]  D. Cameron,et al.  Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling , 2007, Molecular Cancer Therapeutics.

[37]  I. Brandslund,et al.  The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer , 2006, International Journal of Gynecologic Cancer.

[38]  A. Goldhirsch,et al.  Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy , 2006, Breast Cancer Research.

[39]  G. Sledge,et al.  The role of angiogenesis inhibition in the treatment of breast cancer. , 2006, Clinical advances in hematology & oncology : H&O.

[40]  C. Benz,et al.  Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. , 2006, Molecular pharmaceutics.

[41]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[42]  G. Hortobagyi,et al.  Expression of PEA3 and Lack of Correlation Between PEA3 and HER-2/neu Expression in Breast Cancer , 2006, Breast Cancer Research and Treatment.

[43]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[44]  Jun Yao,et al.  Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. , 2006, Cancer research.

[45]  C. Benz,et al.  Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery , 2006, Gene Therapy.

[46]  J. Marks,et al.  Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. , 2006, Biochimica et biophysica acta.

[47]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[48]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[49]  A. Goldhirsch,et al.  Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy , 2005, Breast Cancer Research.

[50]  M. Hung,et al.  Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor , 2005, Molecular and Cellular Biology.

[51]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[52]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[53]  N. Spector,et al.  Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells , 2005, Oncogene.

[54]  P. Leder,et al.  A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. , 2005, Cancer research.

[55]  W. Gullick,et al.  The epidermal growth factor receptor family. , 2005, Endocrine-related cancer.

[56]  G. Adams,et al.  In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. , 2005, Cancer biotherapy & radiopharmaceuticals.

[57]  A. Berezov,et al.  HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. , 2005, DNA and cell biology.

[58]  S. Morrison,et al.  Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein , 2005, Molecular Cancer Therapeutics.

[59]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[60]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[61]  J. Mohler,et al.  Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. , 2005, Cancer research.

[62]  B. Karlan,et al.  Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  A. Margulis,et al.  E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs. , 2005, Cancer research.

[64]  J. Votaw,et al.  Silencing of CXCR4 blocks breast cancer metastasis. , 2005, Cancer research.

[65]  Frank E. Jones,et al.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone , 2004, The Journal of cell biology.

[66]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[67]  M. Freeman.  HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR? , 2004, Cancer cell.

[68]  S. Loibl,et al.  Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. , 2004, Neoplasia.

[69]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[70]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[71]  E. Crawford,et al.  The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial , 2004, The Prostate.

[72]  M. Hung,et al.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[73]  A. Davidoff,et al.  Antiangiogenic gene therapy for cancer treatment. , 2004, Current hematology reports.

[74]  D. El-Ashry,et al.  A Cytoplasmic Substrate of Mitogen-Activated Protein Kinase Is Responsible for Estrogen Receptor-α Down-Regulation in Breast Cancer Cells: The Role of Nuclear Factor-κB , 2004 .

[75]  J. Zhao,et al.  Secreted Antibody/Granzyme B Fusion Protein Stimulates Selective Killing of HER2-overexpressing Tumor Cells* , 2004, Journal of Biological Chemistry.

[76]  G. Adams,et al.  Selection and characterization of HER2/neu-binding affibody ligands. , 2004, Protein engineering, design & selection : PEDS.

[77]  M. Hung,et al.  The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells , 2004, Cancer Research.

[78]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[79]  R. Mehta,et al.  Effect of vitamin D analog (1α hydroxy D5) immunoconjugated to Her‐2 antibody on breast cancer , 2004, International journal of cancer.

[80]  I. Bauerfeind,et al.  Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients , 2004, Clinical Cancer Research.

[81]  T. Waldmann,et al.  Herceptin-Geldanamycin Immunoconjugates , 2004, Cancer Research.

[82]  R. Bast,et al.  Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression* , 2004, Journal of Biological Chemistry.

[83]  P. Span,et al.  Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma , 2003, Cancer.

[84]  Dihua Yu,et al.  Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone , 2003, Cancer.

[85]  S. Swain,et al.  Ongoing adjuvant trials with trastuzumab in breast cancer. , 2003, Seminars in oncology.

[86]  M. Rubin,et al.  E-cadherin expression in primary carcinomas of the breast and its distant metastases , 2003, Breast Cancer Research.

[87]  B. Gumbiner,et al.  Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin , 2003, The Journal of cell biology.

[88]  A. Yang,et al.  Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. , 2003, Cancer research.

[89]  M. Hsiao,et al.  Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody. , 2003, Journal of biomedical science.

[90]  G. Gardani,et al.  Changes in Circulating VEGF Levels in Relation to Clinical Response during Chemotherapy for Metastatic Cancer , 2003, The International journal of biological markers.

[91]  G. Coetzee,et al.  Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. , 2003, Molecular cancer research : MCR.

[92]  Mouldy Sioud,et al.  Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[94]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[96]  Sarel J. Fleishman,et al.  A putative molecular-activation switch in the transmembrane domain of erbB2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Hong Ma,et al.  Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.

[98]  Mi-Sook Lee,et al.  Significance of E-cadherin/β-catenin complex and cyclin D1 in breast cancer , 2002 .

[99]  P. Trail,et al.  Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. , 2002, Journal of medicinal chemistry.

[100]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[101]  B. Pockaj,et al.  ErbB-β-Catenin Complexes Are Associated with Human Infiltrating Ductal Breast and Murine Mammary Tumor Virus (MMTV)-Wnt-1 and MMTV-c-Neu Transgenic Carcinomas* , 2002, The Journal of Biological Chemistry.

[102]  M. Pegram,et al.  Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. , 2002, Seminars in oncology.

[103]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[104]  D. Siwak,et al.  The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[106]  A. Ullrich,et al.  Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.

[107]  M. Lemmon,et al.  The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes* , 2002, The Journal of Biological Chemistry.

[108]  K. Lackey,et al.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. , 2001, Cancer research.

[109]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[110]  E. Small,et al.  Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. , 2001, Seminars in oncology.

[111]  W. Marasco,et al.  Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells , 2001, Cancer Gene Therapy.

[112]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[113]  W. Yung,et al.  Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF , 2001, British Journal of Cancer.

[114]  G. Goodman,et al.  Overexpression of HER-2 in ovarian carcinomas. , 2001, Cancer research.

[115]  K. Sugimachi,et al.  Clinical significance of vascular endothelial growth factor‐C (VEGF‐C) in breast cancer , 2001, Breast Cancer Research and Treatment.

[116]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[117]  Lance A. Liotta,et al.  Cancer: An attractive force in metastasis , 2001, Nature.

[118]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[119]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[120]  H. Scher.  HER2 in prostate cancer--a viable target or innocent bystander? , 2000, Journal of the National Cancer Institute.

[121]  A. Vincent-Salomon,et al.  High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases , 2000, Histopathology.

[122]  S. Sharpe,et al.  Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers. , 2000, Biochemistry.

[123]  R. Mehta,et al.  Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. , 2000, European journal of cancer.

[124]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[125]  Donald M. O'Rourke,et al.  Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo , 2000, Nature Biotechnology.

[126]  J. Drebin,et al.  Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. , 2000, Cancer research.

[127]  C. Boswell,et al.  Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. , 1999, Surgery.

[128]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[129]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[130]  N. Hellyer,et al.  ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. , 1998, The Biochemical journal.

[131]  C. Boswell,et al.  Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. , 1998, The Journal of surgical research.

[132]  H. Juhl,et al.  HER-2/neu Is Rate-limiting for Ovarian Cancer Growth , 1997, The Journal of Biological Chemistry.

[133]  S. Hirohashi,et al.  Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. , 1996, Oncogene.

[134]  M. Dowsett,et al.  Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. , 1995, Cancer research.

[135]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[136]  D. Slamon,et al.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.

[137]  S. Hirohashi,et al.  Overexpression of c‐erbB‐2 protein in gastric cancer. Its correlation with long‐term survival of patients , 1993, Cancer.

[138]  T. Singleton,et al.  Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.

[139]  Takuma Sasaki,et al.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. , 1991, Cancer research.

[140]  A. Ullrich,et al.  Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling , 1988, Molecular and cellular biology.

[141]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[142]  T. Kuroki,et al.  Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. , 1986, Journal of the National Cancer Institute.

[143]  G. Steger,et al.  HER-2-Positive Breast Cancer , 2012, BioDrugs.

[144]  R. O'Regan,et al.  Targeting Angiogenesis in Advanced Breast Cancer , 2012, BioDrugs.

[145]  V. Kaklamani,et al.  HER2-Positive Breast Cancer , 2012, Drugs.

[146]  K. Cheng,et al.  RNA Interference for Cancer Therapy , 2009 .

[147]  S. Deutscher,et al.  Phage peptide display. , 2008, Handbook of experimental pharmacology.

[148]  O. Gofrit,et al.  Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer. , 2007, Cancer research.

[149]  A. Yang,et al.  CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo , 2005, Cancer Gene Therapy.

[150]  W. Zimmermann,et al.  Activated Neu/ErbB-2 Induces Expression of the Vascular Endothelial Growth Factor Gene by Functional Activation of the Transcription Factor Sp 1 , 2004, Angiogenesis.

[151]  B. Seliger,et al.  Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines , 2004, International journal of cancer.

[152]  L. Beckman,et al.  Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. , 2004, European journal of cancer.

[153]  R. Neve,et al.  The role of overexpressed HER2 in transformation. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  Y. Yarden,et al.  The basic biology of HER2. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[155]  R. Mehta,et al.  Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1alpha-hydroxyvitamin D5. , 2000, International journal of oncology.

[156]  A. Vincent-Salomon,et al.  Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns , 1996, Cancer.